4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Aligos Therapeutics, Inc. (ALGS) operates in the Biotechnology industry and is headquartered in South San Francisco, United States with about 82 employees. Its market capitalization is roughly $25 million. In the fiscal year ended 2025-12-31, ALGS reported $2M in revenue and ($24M) in net income.
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases.
Interactive charts & full statements → Open the ALGS valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $2M | $4M | $16M | $14M | — |
| Operating Income (EBIT) | ($88M) | ($89M) | ($88M) | ($98M) | — |
| Net Income | ($24M) | ($131M) | ($88M) | ($96M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $3M | $0M | $1M | $1M | $0M |
| Operating Income (EBIT) | ($27M) | ($22M) | ($28M) | ($19M) | ($19M) |
| Net Income | ($23M) | ($20M) | ($32M) | ($16M) | $43M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $88M | $70M | $152M | $147M | — |
| Total Liabilities | $35M | $99M | $59M | $43M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ALGS viewer.
About TickerBase · Data methodology & sources